Live Chart

O 6367.7

H 6367.7

L 6367.7

VOL 529

Dr Reddys Laboratories Performance

Days Range

Low: ₹6,363.00
High: ₹6,494.05
Previous Close ₹6,363.95
Open ₹6,367.70
Volume 3,68,322
Day’s Range ₹6,363.00 - ₹6,494.05
52W Range ₹4,297.00 - ₹6,494.05
Market Cap ₹1,06,155 Cr

Fundamentals of Dr Reddys Laboratories

ROCE (TTM) 25.41%
P/E Ratio (TTM) 20.3
P/B Ratio 4.16
Industry P/E 36.45
Debt to Equity 0.05
ROE 19.97%
EPS (TTM) 313.42
Dividend Yield 0.63%
Book Value 1,528
Face Value 5

Financials of Dr Reddys Laboratories

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales6,315.26,757.96,902.67,236.8
Profit before tax1,329.11,8501,916.71,829.1
Operating Profit960.11,4051,482.21,380.9
Net Profit960.11,4051,482.21,380.9
EPS in Rs57.7984.5589.0982.94

About Dr Reddys Laboratories


Dr Reddy’s Laboratories was incorporated in 1984 in Hyderabad. It was established by Dr Anji Reddy with an initial capital outlay of ₹25 lakh. Mr. Reddy was one of the pioneers of the active pharmaceutical ingredients or APIs industry in India. Before establishing Dr. Reddy’s Laboratories, he had already co-founded two bulk drug manufacturing ventures.

The company made its beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (APIs) and commenced operations with a single drug in a 60-tonne facility near Hyderabad. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Thereafter, they entered the international market with exports of Methyldopa. In the year 1987, the company obtained the first USFDA approval for Ibuprofen API.

In 1991, the company began production of Omeprazole, which is one of its most popular drugs. In 1993, the Dr. Reddy’s Research Foundation was established, which focused on drug discovery, especially for cancer and diabetes. In 1998, they started their biologics business to offer affordable medicine to the Indian consumer. In 2003, the company launched its first generic product, i.e. Ibuprofen, under their label in the US. In 2019, the company entered the nutrition segment in India through the launch of Celevida.

Business Segments

Dr. Reddy’s offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company focuses on areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s is today a global company with a strong presence abroad. Its major markets include – the USA, India, Russia, and Europe. 

The company has primarily 3 businesses:

  1. Pharmaceutical services and active ingredients production – This is the largest source of revenue for the company, bringing in roughly 83% of the revenue in FY 2022. As of September 2023, the company offers 400+ generic drugs at affordable costs by leveraging its integrated operations. Drugs related to the nervous system bring in the most revenue.
  2. Global generic drug production – Dr. Reddy’s Laboratories works on API development to help its own generic drugs business become cheaper as well as to launch products in the market faster than its competitors.
  3. Proprietary Products – This mostly involves the company developing various formulas to enhance efficiency and ease of use, among other factors.

As of March 2023, the company had 40 subsidiary companies abroad and 9 subsidiaries in India. Major ones include Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories SA, and Betapharm Arzneimittel GmbH, among others. 

Key Personnel

Erez Israeli, CEO

Erez Israeli is the Chief Executive Officer of Dr. Reddy’s Laboratories. He joined the company in April 2018 as Chief Operating Officer before becoming CEO in July 2019. Mr. Israeli has an MBA from Bar-Ilan University, Israel, as well as over 30 years of experience. He had earlier worked at Enzymotec, where he was the President and CEO. Before that, he worked at Teva Pharmaceuticals for 23 years. He has held a multitude of positions, especially in the field of sales and marketing.

G V Prasad, Co-chairman and MD

Mr. Prasad joined the company in 1990. He oversaw Dr. Reddy’s growth from a mid-sized domestic operation to a major global pharma brand today, with a presence in 66 countries and a valuation of billions of dollars. His focus is on research, innovation, transparency, business ethics and leaner corporate structures. He also focuses on mentoring leaders driving innovation in science, technology and digitalisation.

Corporate Actions

Bonus Shares

Dr Reddy’s Laboratories had announced a bonus share in 2006 in the ratio of 1:1.

Stock Splits

Dr Reddy’s Laboratories had last split its shares from a face value of ₹10 to ₹5 in 2001.

Dr Reddys Laboratories has not announced any rights issues or buyback of shares so far.

Mergers and Acquisitions

  • In 2022-23, Dr. Reddy’s Holdings Limited got merged with Dr Reddy’s Laboratories Ltd. The merger became effective in April 2022.
  • DRS LLC in Russia merged into Dr. Reddy’s Laboratories LLC in July 2022. 
  • In 2017, Dr. Reddy’s Laboratories completed the acquisition of a 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC), based out of Kolkata, for a consideration of ₹2.05 crore.
  • In 2016, Dr. Reddy’s Laboratories acquired 6 OTC brands from Ducere Pharma to enter the consumer health field.
  • In 2002, the company had made its first overseas acquisition in the form of BMS Laboratories Ltd. and Meridian Healthcare in the UK.

Financial Highlights

  • The company’s sales revenue has gone up by more than 100% in the period between March 2013 and March 2023.
  • On the other hand, the company’s net profits have increased by nearly 200% in the same period.
  • The company’s net cash flows have been volatile over the past years. From being in negative for the last few years, it increased to ₹1,286 crore in FY 2021, dropped to ₹3 in FY 2022 and further declined to -₹907 in FY 2023.
Parent Organisation Dr. Reddy's
Founded 1984
Managing Director K Satish Reddy

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Mankind Pharma Ltd ₹87,626.72


35.15 (-1.61%)

2148 - 2215
Cipla Ltd ₹117,369.89


11.65 (0.80%)

1449.75 - 1482.35
Torrent Pharmaceuticals Ltd ₹88,295.34


18.95 (0.73%)

2598.1 - 2638.6
Zydus Lifesciences Ltd ₹91,584.23


18.95 (2.10%)

898.1 - 937
Sun Pharmaceuticals Industries Ltd ₹373,756.40


3.20 (0.21%)

1550.4 - 1568.45

What's Trending


What is the Share price of Dr Reddys Laboratories (DRREDDY)?

Dr Reddys Laboratories (DRREDDY) share price as of February 23, 2024, on NSE is Rs 6,425.00 (NSE) and Rs 6,430.95 (BSE) on BSE.

Can I buy Dr Reddys Laboratories (DRREDDY) shares?

Yes, You can buy Dr Reddys Laboratories (DRREDDY) shares by opening a Demat account with Angel One.

How do I buy Dr Reddys Laboratories (DRREDDY) from Angel One?

Dr Reddys Laboratories (DRREDDY) share can be brought through the following modes:
  1. Direct investment: You can buy Dr Reddys Laboratories (DRREDDY) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Dr Reddys Laboratories (DRREDDY) shares.

What is the total Asset of Dr Reddy?

The total asset of Dr. Reddy is Rs. 29, 746 Crores.

What is the main business of Dr Reddy?

Dr. Reddy’s produces and sells a variety of medications both domestically and abroad. The business produces about 190 drugs, 60 active pharmaceutical ingredients (APIs) used in the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology items.

Who are the promoters of Dr Reddy?

The promoters are Dr. Reddy’S Holdings Limited, APS Trust, Samrajyam Reddy Kallam, Satish Reddy Kallam, Gunupati Venkateswara Prasad (Huf), G.V.Prasad, K.Satish Reddy (HUF), Anuradha Gunupati, G Anuradha, K. Deepti Reddy, G.V. Sanjana Reddy, G. Mallika Reddy, Sharathchandra Reddy Gunupati, K Shravya Reddy, K Vishal Reddy, VSD Holdings & Advisory LLP.

Who is the CEO of Dr Reddy?

Erez Israeli is the CEO of Dr. Reddy.